Active Ingredient History

  • Now
Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease, a rare lysosomal storage disorder (LSD). Chemically, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$619.9200 - $7997.5400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

acid alpha-glucosidase | acid-alpha glucosidase | acid alpha-glucosidase, human | acid maltase | acid maltase, human | aglucosidase alfa | aglucosidase alpha | alglucosidase alfa | alglucosidase alfa (genetical recombination) | alpha-1,4-glucosidase | alpha-glucosidase | gaa protein, human | glucosidase alfa | glucosidase, alpha; acid (pompe disease, glycogen storage disease type ii), human | human acid alpha-glucosidase | lumizyme | lyag protein, human | lysosomal alpha-glucosidase | lysosomal alpha-glucosidase, human | myozyme | recombinant adeno-associated virus acid alpha-glucosidase | recombinant alpha-galactosidase a | recombinant human acid alpha-glucosidase | rhgaa


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue